← Leaderboards
William F Balistreri
Children'S Hospital Med Ctr (Cincinnati)
$124,159
Attributed
$124,159
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $37.3K · FY2005–08$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$124,159 · 6
By mechanism
M01$124,159 · 6
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Med Ctr (Cincinnati)
Same institution · by research overlap
- Jorge A. Bezerra$30,943,165
- James E. Heubi$41,505,537
- Gregory M Tiao$5,042,111
- Brad Wayne Warner$9,603,672
- Lori J Stark$5,093,805
Others in their field
Top investigators on “Week”
- David Heimbrook · Leidos Biomedical Research, Inc.$86,943,263
- Sharon L. Walsh · University Of Kentucky$81,731,115
- George R Seage · Abt Associates, Inc.$76,449,865
- David D. McManus · Univ Of Massachusetts Med Sch Worcester$64,700,115
- Bryan O Buchholz · University Of Massachusetts Lowell$62,149,237
- Anita L Lopez · University Of Hawaii$59,384,372
Research focus
WeekBody CompositionBody Mass IndexChenodeoxycholateChildCholestasisChronicChronic Disease /DisorderClinical ResearchBehaviorCognitiveCombined Modality TherapyComputer Retrieval Of Information On Scientific Projects DatabaseCystic FibrosisEnrollmentFollow-UpFundingGrantGrowthHealth Related Quality Of LifeHepatitis CHepatitis C VirusHuman SubjectHuman Therapy Evaluation
Grant awards (7)
CLINICAL TRIAL: PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV$5,201
M01 · FY2008 · RR · contact PI
PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV$37,327
M01 · FY2007 · RR · contact PI
PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV$23,038
M01 · FY2006 · RR · contact PI
BIOAVAILABILITY OF URSOCARB COMPARED TO ACTIGALL IN LIVER DISEASE AND CF$590
M01 · FY2006 · RR · contact PI
BIOAVAILABILITY OF URSOCARB COMPARED TO ACTIGALL IN LIVER DISEASE AND CF$923
M01 · FY2005 · RR
BIOAVAILABILITY OF URSOCARB VS ACTIGALL IN CHRONIC CHOLESTATIC LIVER DISEASE$28,540
M01 · FY2001 · RR
BIOAVAILABILITY OF URSOCARB VS ACTIGALL IN CHRONIC CHOLESTATIC LIVER DISEASE$28,540
M01 · FY2000 · RR